FLT3 G697S

CI-VAR-00001790Explore in graph →CIViC 3212

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia2
FLT3 G697S	Gilteritinib	Predictive	D	Supports Resistance	3	submitted	EID8898 Using in vitro proliferation assay in Ba/F3 cells, it was found that the cells with FLT3-ITD G697S exhibited potent resistance to Gilteritinib. Similar resistance was found in cells bearing FLT3-ITD F… (full text at CIViC) PMID 32040554 · Tarver et al., 2020 · Open in CIViC	civic
FLT3 G697S	Gilteritinib	Predictive	D	Supports Reduced Sensitivity	4	submitted	EID9022 Gilteritinib is the first FLT3 inhibitor approved by the Food and Drug administration (FDA) as monotherapy in adult refractory/relapse acute myeloid leukemia (R/R AML) patients with FLT3-ITD and/or ty… (full text at CIViC) PMID 32040554 · Tarver et al., 2020 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.